Immunotherapy as Second-line Treatment in Grade 3 Neuroendocrine Carcinomas: A Prospective Case Series from an ENETS Center of Excellence
Introduction: Metastatic WHO grade 3 extra-pulmonary neuroendocrine carcinomas (EP-NEC) have a poor prognosis and optimal treatment after first-line platinum-etoposide chemotherapy remains unclear. A recent, small phase II study combining ipilimumab and nivolumab showed promising results
Aim(s): Evaluation of immunotherapy in NETwerk, an ENETS Center of Excellence, as new treatment option in EP-NEC
Materials and methods: Patient characteristics of all EP-NEC, discussed at the NET-specific MDT (NET MDT), were prospectively recorded between August 2018 and November 2019. Progression-free survival (PFS) of patients receiving immunotherapy was calculated
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.